The Bill & Melinda Gates Foundation has committed an investment of USD 5 million to accelerate the impact of Bactolife's technology platform to develop Binding Proteins, a novel biologic solution to reduce the risk of gut infections in humans and animals.
Mads Laustsen, CEO at Bactolife, said that “with this investment, Bactolife is able to boost our efforts in our technology platform, allowing us to reach our end customers faster and with affordable products that can benefit the many – thereby potentially impacting millions of people's lives worldwide.”
Novo Holdings led a previous €7 million investment in 2021. Sebastian Søderberg, deputy CEO at Bactolife, added, “we are proud of and humbled for the confidence the Bill & Melinda Gates Foundation has shown us. We are pleased to have funding from both Novo Holdings and the Gates Foundation, and regard this as a strong validation of Bactolife's potential to improve human and animal health worldwide and make these products accessible in developed and developing countries.”
Gut infections, a major global threat
Today, most gut infections are treated with antibiotics that are either very expensive or contribute to the spread of antibiotic-resistant bacteria. Bactolife takes a unique approach to gut health for the greater good of humans and animals by developing breakthrough Binding Proteins that can reduce the risk of developing gut infections at an affordable price. With Bactolife's technology platform and the investment made by the Bill & Melinda Gates Foundation, Binding Proteins can be formulated into food and feed products, making them easy to ingest, the company said.
